|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-8-4
|
|
pubmed:abstractText |
To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA-4Ig), a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has remained active despite methotrexate (MTX) therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:ArandaRichardR,
pubmed-author:BeckerJean-ClaudeJC,
pubmed-author:DougadosMaximeM,
pubmed-author:DurezPatrickP,
pubmed-author:EmeryPaulP,
pubmed-author:KremerJoel MJM,
pubmed-author:LiTracyT,
pubmed-author:MorelandLarry WLW,
pubmed-author:NuamahIsaac FIF,
pubmed-author:ShergyWilliamW,
pubmed-author:SibiliaJeanJ,
pubmed-author:SteinfeldSergeS,
pubmed-author:TindallElizabethE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2263-71
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16052582-Antibody Formation,
pubmed-meshheading:16052582-Arthritis, Rheumatoid,
pubmed-meshheading:16052582-Dose-Response Relationship, Drug,
pubmed-meshheading:16052582-Double-Blind Method,
pubmed-meshheading:16052582-Health Status,
pubmed-meshheading:16052582-Humans,
pubmed-meshheading:16052582-Immunoconjugates,
pubmed-meshheading:16052582-Questionnaires,
pubmed-meshheading:16052582-Remission Induction,
pubmed-meshheading:16052582-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
|
|
pubmed:affiliation |
Center for Rheumatology, Albany, NY 12206, USA. jkremer@joint-docs.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
